Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Cathinone

or [[:Category:Antianginals|Antianginal]]

Use the filters below to narrow your results.

3-MMC (1) · Agomelatine (1) · Amlodipine (1) · Amoxapine (1) · Butylone (1) · Cathinone (1) · Clomipramine (1) · Desipramine (1) · Diltiazem (1) · Duloxetine (1) · Ephylone (1) · Ethcathinone (1) · Ethylone (1) · Hexedrone (1) · Imipramine (1) · Isocarboxazid (1) · Isosorbide (dinitrate, mononitrate) (1) · Levomilnacipran (1) · Maprotiline (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · Milnacipran (1) · Moclobemide (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Nefazodone (1) · Nifedipine (1) · Nitroglycerin (glyceryl trinitrate, GTN) (1) · Pentedrone (1) · Phenelzine (1) · Protriptyline (1) · Reboxetine (1) · Sertraline (1) · Tianeptine (1) · Tranylcypromine (1) · Trimipramine (1) · Verapamil (1)

None (15) · Anafranil (1) · Aurorix (1) · Calan, Calan SR, Verelan, Verelan PM, Isoptin SR (1) · Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Imdur (mononitrate ER), Isordil (dinitrate); generics; with hydralazine as BiDil for HFrEF in self-identified Black patients (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Nitrostat, Nitrolingual, NitroMist, Nitro-Bid, Nitro-Dur, Minitran, Rectiv (1) · Norpramin (1) · Norvasc, Katerzia (1) · Parnate (1) · Procardia, Procardia XL, Adalat CC, Afeditab CR (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)

None (4) · Cathinone analogue; monoamine reuptake inhibitor (2) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. (1) · '"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1)

None (32) · 2.5-5 mg PO once daily; titrate to 10 mg/d (1) · 25 mg (1) · ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) · ER 30-60 mg PO once daily; immediate-release 10 mg PO TID (now rarely used for hypertension due to reflex tachycardia) (1) · IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1) · Isosorbide mononitrate ER: 30-60 mg PO once daily in the morning, titrate to 120-240 mg/d; isosorbide dinitrate IR: 5-20 mg PO TID with a 12-14 hour nitrate-free interval to prevent tolerance (1) · SL 0.3-0.6 mg every 5 minutes up to 3 doses for acute angina (call EMS if not resolved after the third); IV infusion 5-10 mcg/min titrated; transdermal patch 0.2-0.4 mg/hr for 12-14 hours daily (nitrate-free interval prevents tolerance) (1)

None (32) · 10, 20 mg IR capsules; 30, 60, 90 mg ER tablets (1) · 2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL (1) · IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL (1) · Mononitrate 10, 20 mg IR; 30, 60, 120 mg ER; dinitrate 5, 10, 20, 30, 40 mg IR and ER (1) · SL 0.3, 0.4, 0.6 mg tablets; lingual spray 0.4 mg/spray; ER 2.5-9 mg capsules; transdermal patch 0.1-0.8 mg/hr; 2% ointment; 0.4% rectal ointment; 5 mg/mL IV (1)

None (32) · 10 mg/d (1) · 120 mg/d (ER); IR not for chronic hypertension (1) · 200 mg/d (1) · 240 mg/d (mononitrate ER); 160 mg/d (dinitrate) (1) · Indication-specific; titrated to effect (1) · ~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster (1) · ~480 mg/d (oral); IV per protocol (1)

None (31) · IV (3) · lingual spray (1) · MI reports) (1) · multiple ER formulations) (1) · Oral (4) · Oral (IR (1) · Oral (IR and multiple ER) (1) · oral ER (1) · Oral; sublingual IR is discouraged (uncontrolled BP drops (1) · rectal (1) · Sublingual (1) · sublingual (dinitrate) (1) · topical (1) · transdermal (1)

None (31) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) · IR 20 minutes; ER ~6 hours (1) · IV: 1-3 minutes (SVT termination); PO IR: 30-60 minutes; ER: hours (1) · IV: 3-7 minutes (rate control); PO IR: 30-60 minutes; ER: hours (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · SL/spray: 1-3 minutes; IV: minutes; patch: 30-60 minutes (1) · SL: 2-5 minutes; PO mononitrate: 30-60 minutes (1)

None (31) · 24 hours (1) · Chronic daily dosing (1) · IR 4-8 hours; ER 24 hours (1) · IR: 4-8 hours; ER: 24 hours (1) · IR: 6-8 hours; ER: 24 hours (1) · Long (1) · Mononitrate ER: 12-24 hours; dinitrate IR: 4-6 hours (1) · SL: 30 minutes; patch: 12-14 hours; IV continuous (1)

None (31) · 1-3 minutes (very short)'"`UNIQ--ref-00000C0F-QINU`"' (1) · 2-5 hours (IR); ER formulations extend functional duration via osmotic/matrix release'"`UNIQ--ref-0000074D-QINU`"' (1) · 3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)'"`UNIQ--ref-00000642-QINU`"' (1) · 3-7 hours (IR); functional 24 hours (ER)'"`UNIQ--ref-00000A6B-QINU`"' (1) · 30-50 hours'"`UNIQ--ref-00000078-QINU`"' (1) · Mononitrate ~5 hours; dinitrate ~1 hour'"`UNIQ--ref-00001461-QINU`"' (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (31) · 64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"' (1) · Mononitrate ~100% (no first-pass; the principal advantage over dinitrate); dinitrate ~20%'"`UNIQ--ref-00001462-QINU`"' (1) · ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' (1) · ~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' (1) · ~50% (highly variable) (1) · ~50% IR (extensive first-pass via CYP3A4); ER products release-rate-limited'"`UNIQ--ref-0000074E-QINU`"' (1)

None (31) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; alternative antihypertensives generally preferred. Crosses placenta.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; labetalol/nifedipine generally preferred. Crosses placenta.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Oral nifedipine is one of the preferred agents for severe hypertension in pregnancy and for tocolysis in preterm labor.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Used in obstetric emergencies (uterine relaxation, severe hypertension) when needed; otherwise limited routine use.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (31) · Rx-only (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US (6)